Relmada Therapeutics, Inc.
$0.33
0 (1.31%)
RLMD Price Chart
| Basic | |
|---|---|
| Market Cap | $9.2M |
| Price | $0.33 |
| 52 Week Range | 0.28-7.223 |
| Beta | 0.41 |
| Margins | |
| Gross Profit Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Valuation (TTM) | |
| P/E Ratio | -0.10 |
| Price to Sales Ratio | 0.00 |
| Price to Book Ratio | 0.22 |
| PEG Ratio | -0.01 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
20
Website
IPO Date
2014-06-20T00:00:00.000Z
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Phone
786 629 1376
Address
2222 Ponce de Leon Boulevard, Coral Gables, FL, 33134, US
CIK
0001553643